PatrickJosephGroharMDPhD

Pediatric Hematology & Oncology • Ann Arbor, MI

Associate Professor of Pediatrics Director of Translational Research Center of Childhood Cancer Research Children’s Hospital of Philadelphia University of Pennsylvania Perelman School of Medicine

Join to view full profile

Dr. Grohar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Grohar's full profile

Already have an account?

Office
1500 E Medical Center Dr
Ann Arbor, MI 48109
Phone+1 734-936-4000

Education & Training

National Cancer InstituteFellowship, Pediatric Hematology/Oncology, 2006 - 2009
Johns Hopkins UniversityResidency, Pediatrics, 2003 - 2006
Wayne State University School of MedicineClass of 2003

Certifications & Licensure

MI State Medical License 2015 - 2025
PA State Medical License 2020 - 2024
TN State Medical License 2011 - 2017
MD State Medical License 2006 - 2012
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

SARC037: a Phase I/II Study to Evaluate the Safety of Trabectedin in Combination with Irinotecan in Ewing Sarcoma Patients Start of enrollment: 2021 Jan 05
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2

Publications & Presentations

PubMed

Exploiting divergent mechanisms of trabectedin for bone tumors.
Zachary P Tolstyka, Patrick J Grohar
Molecular Therapy. Oncology. 2025-06-18
Comprehensive DSRCT multi-omics analyses unveil CACNA2D2 as a diagnostic hallmark and super-enhancer-driven EWSR1::WT1 signature gene.
Florian Henning Geyer, Alina Ritter, Seneca Kinn-Gurzo, Tobias Faehling, Jing Li
Cancer Communications. 2025-03-15
Molecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children's Oncology Group.
Riaz Gillani, David S Shulman, Natalie J DelRocco, Kelly Klega, Ruxu Han
Medrxiv. 2025-01-20

Press Mentions

AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042 (AIT-102)April 24th, 2022
GDF6-CD99 Signaling Regulates Src and Ewing Sarcoma GrowthNovember 3rd, 2020
CHOP Researchers Working Hard to Unlock the Mysteries of Rare Bone CancerNovember 18th, 2019
Join now to see all

Grant Support

The interface of transcription, DNA damage and epigenetics: A therapeutic vulnerability of the EWS-FLI1 transcription factorUNIVERSITY OF MICHIGAN AT ANN ARBOR2024–2028
The interface of transcription, DNA damage and epigenetics: A therapeutic vulnerability of the EWS-FLI1 transcription factorUNIVERSITY OF MICHIGAN AT ANN ARBOR2024–2028
A collaborative approach to analyze and target the EWS-FLI1 transcription factor in patients with Ewing sarcomaSARC2019–2024